MicroRNA-135a Regulates VEGFC Expression and Promotes Luteinized Granulosa Cell Apoptosis in Polycystic Ovary Syndrome

Reproductive Sciences - Tập 27 - Trang 1436-1442 - 2020
Yifang Wei1,2, Shenglian Lu3, Yu Hu1, Li Guo1, Xiaoyu Wu4, Xing Liu1, Yun Sun2,5
1Center for Reproductive Medicine, No. 455 Hospital of the Chinese People’s Liberation Army, Second Military Medical University, Shanghai, China
2Center for Reproductive Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
3Department of Obstetrics and Gynecology, Changhai Hospital, Second Military Medical University, Shanghai, China
4Surgical Intensive Care Unit, The Children’s Hospital, Zhejiang University School of Medicine, Zhejiang, China
5Shanghai Key Laboratory for Assisted Reproduction and Reproductive Genetics, Shanghai, China

Tóm tắt

Androgen is known to regulate microRNA-135a (miR-135a) and can be regulated by androgen, suggesting that it may contribute to polycystic ovary syndrome (PCOS) with hyperandrogenism. However, its roles and mechanisms of action in PCOS are unknown. In this study, the role and molecular mechanisms underlying miR-135a in granulosa cells (GCs) in PCOS were evaluated. miR-135a expression was upregulated in patients with PCOS and in GCs isolated from patients compared with that in the respective controls (P < 0.01), as determined by RT-qPCR. The overexpression of miR-135a inhibited GC proliferation and induced GC apoptosis, as observed by CCK-8 assay and apoptosis assay. Furthermore, miR-135a overexpression increased the expression of double-strand break maker, γH2AX, as confirmed by western blotting. Our results further suggest that these effects were mediated via downregulation of vascular endothelial growth factor C (VEGFC), which was identified as a direct target of miR-135a. Moreover, levels of VEGFC and miR-135a expression showed a negative correlation. These findings indicate that miR-135a promotes apoptosis and the DNA damage response in GCs in PCOS, likely via VEGFC signaling. This study provides novel insights into GC dysregulation in PCOS and suggests that miR-135a is a promising therapeutic target for PCOS treatment.

Tài liệu tham khảo

Glintborg D, Andersen M. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol. 2010;26:281–96. ESHRE TR, Group APCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25. Yildiz BO, Bozdag G, Yapici Z, Esinler I, Yarali H. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum Reprod. 2012;27:3067–73. Maciel GA, Baracat EC, Benda JA, Markham SM, Hensinger K, Chang RJ, et al. Stockpiling of transitional and classic primary follicles in ovaries of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89:5321–7. Jahromi BN, Mosallanezhad Z, Matloob N, Davari M, Ghobadifar MA. The potential role of granulosa cells in the maturation rate of immature human oocytes and embryo development: a co-culture study. Clinical and experimental reproductive medicine. 2015;42:111–7. Homburg R. Involvement of growth factors in the pathophysiology of polycystic ovary syndrome. Gynecol Endocrinol. 1998;12:391–7. Tiwari M, Prasad S, Tripathi A, Pandey AN, Ali I, Singh AK, et al. Apoptosis in mammalian oocytes: a review. APOPTOSIS. 2015;20:1019–25. Erickson GF, Magoffin DA, Garzo VG, Cheung AP, Chang RJ. Granulosa cells of polycystic ovaries: are they normal or abnormal? Hum Reprod. 1992;7:293–9. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998;83:3984–91. Ambros V. MicroRNAs: tiny regulators with great potential. CELL. 2001;107:823–6. Wen-Na Yuan LT. MicroRNA320 inhibits insulin resistance in patients with PCOS through regulating erk12 signaling pathway. BIOMED RES-TOKYO. 2017;28:4946–9. Fu X, He Y, Wang X, Peng D, Chen X, Li X, et al. MicroRNA-16 promotes ovarian granulosa cell proliferation and suppresses apoptosis through targeting PDCD4 in polycystic ovarian syndrome. Cell Physiol Biochem. 2018;48:670–82. Anja Elaine Sørensen MLWS, Dalgaard ALT. MicroRNAs related to polycystic ovary syndrome (PCOS). GENES-BASEL. 2014;5:684–708. Cho S, Mutlu L, Grechukhina O, Taylor HS. Circulating microRNAs as potential biomarkers for endometriosis. Fertil Steril. 2015;103:1252–60. Wan X, Pu H, Huang W, Yang S, Zhang Y, Kong Z, et al. Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy. Oncotarget. 2016;7:51284–300. Kroiss A, Vincent S, Decaussin-Petrucci M, Meugnier E, Viallet J, Ruffion A, et al. Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. ONCOGENE. 2015;34:2846–55. Catteau-Jonard S, Jamin SP, Leclerc A, Gonzales J, Dewailly D, di Clemente N. Anti-Mullerian hormone, its receptor, FSH receptor, and androgen receptor genes are overexpressed by granulosa cells from stimulated follicles in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:4456–61. Wei Y, Lai X, Yu S, et al. Exosomal miR-221/222 enhances tamoxifen resistance in recipient ER-positive breast cancer cells. Breast Cancer Res Treat. 2014;147:423–31. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med. 2006;12:440–50. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called “hyperthecosis”. OBSTET GYNECOL SURV. 1982;37:59–77. Lin F, Li R, Pan ZX, et al. miR-26b promotes granulosa cell apoptosis by targeting ATM during follicular atresia in porcine ovary. PLoS One. 2012;7:e38640. Chen Y, Heneidi S, Lee J, Layman LC, Stepp DW, Gamboa GM, et al. miRNA-93 inhibits GLUT4 and is overexpressed in adipose tissue of polycystic ovary syndrome patients and women with insulin resistance. DIABETES. 2013;62:2278–86. Dokras A, Sarwer DB, Allison KC, Milman L, Kris-Etherton PM, Kunselman AR, et al. Weight loss and lowering androgens predict improvements in health-related quality of life in women with PCOS. J Clin Endocrinol Metab. 2016;101:2966–74. Hominick D, Silva A, Khurana N, et al. VEGF-C promotes the development of lymphatics in bone and bone loss. ELIFE. 2018;7:e34323. Fang S, Nurmi H, Heinolainen K, Chen S, Salminen E, Saharinen P, et al. Critical requirement of VEGF-C in transition to fetal erythropoiesis. BLOOD. 2016;128:710–20. Zhao L, Zhu Z, Yao C, Huang Y, Zhi E, Chen H, et al. VEGFC/VEGFR3 signaling regulates mouse spermatogonial cell proliferation via the activation of AKT/MAPK and cyclin D1 pathway and mediates the apoptosis by affecting caspase 3/9 and Bcl-2. Cell Cycle. 2018;17:225–39. Zheng Q, Zhou F, Cui X, Liu M, Li Y, Liu S, et al. Novel serum biomarkers detected by protein array in polycystic ovary syndrome with low progesterone level. Cell Physiol Biochem. 2018;46:2297–310.